Albertas Ulys
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Albertas Ulys has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Feliksas Jankevicius
National Cancer Institute of Lithuania Vilnius Lithuania
7 shared publications - Alvydas Vezelis
National Cancer Institute, Santariskiu Street 1, Vilnius, LT 08660, Lithuania
5 shared publications M. Kincius
4 shared publications- Arnas Bakavicius
Clinic of Gastroenterology, Nephro-Urology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. Ciurlionio st. 21/27, LT-03101 Vilnius, Lithuania
3 shared publications I. Naruseviciute
3 shared publications- Sonata Jarmalaite
Institute of Biosciences, Life Sciences Center, Vilnius University
3 shared publications
Latest Publications
- 30 December 2021
- Published by Wiley in The Prostate
- Vol. 82 (4) , 475-482
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study
Background: Despite novel agents have been introduced to treat castration resistant prostate cancer (CRPC) during the last decade, up to one‐third of CRPC patients face primary resistance to new generation compounds. Therefore, sensitive molecular tools are urgently needed for reliable treatment selection and response prediction. This study aimed to evaluate urinary miRNAs and blood circulating androgen receptor (AR) transcript level as a tool for noninvasive outcome prediction for CRPC patients undergoing abiraterone acetate (AA) therapy.Methods: Prostate cancer‐specific miR‐148a, ‐365, ‐375, and ‐429 were analyzed in 129 urine samples collected from 100 CRPC patients before and during AA therapy via quantitative reverse transcription PCR. To test the prognostic value, urinary miRNA levels alone, as well as combined with AR level were associated with progression‐free survival (PFS) and overall survival (OS).Results: Level of urinary miR‐375 was the highest in CRPC in comparison to noncancerous controls, as well as in combination with miR‐429 was predictive for short PFS in AA‐treated patients (HR = 2.2, 95% CI: 1.1–4.2, p = 0.023). Especially high prognostic power of all analyzed miRNAs was observed in CRPC cases with high blood AR levels. For PFS prediction a tandem of miR‐429 and high AR reached HR of 5.0 (95% CI: 2.2–11.8, p < 0.001), while for prediction of OS the best combination was demonstrated by miR‐148a and AR with HR of 3.1 (95% CI: 1.4–7.1, p = 0.006).Conclusions: Urinary miRNAs could be used as prognostic biomarkers for CRPC patients to predict response to AA therapy, especially for the cases with high blood AR levels.
- 30 December 2021
- Published by Wiley in The Prostate
- Vol. 82 (4) , 475-482
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study
Background: Despite novel agents have been introduced to treat castration resistant prostate cancer (CRPC) during the last decade, up to one‐third of CRPC patients face primary resistance to new generation compounds. Therefore, sensitive molecular tools are urgently needed for reliable treatment selection and response prediction. This study aimed to evaluate urinary miRNAs and blood circulating androgen receptor (AR) transcript level as a tool for noninvasive outcome prediction for CRPC patients undergoing abiraterone acetate (AA) therapy.Methods: Prostate cancer‐specific miR‐148a, ‐365, ‐375, and ‐429 were analyzed in 129 urine samples collected from 100 CRPC patients before and during AA therapy via quantitative reverse transcription PCR. To test the prognostic value, urinary miRNA levels alone, as well as combined with AR level were associated with progression‐free survival (PFS) and overall survival (OS).Results: Level of urinary miR‐375 was the highest in CRPC in comparison to noncancerous controls, as well as in combination with miR‐429 was predictive for short PFS in AA‐treated patients (HR = 2.2, 95% CI: 1.1–4.2, p = 0.023). Especially high prognostic power of all analyzed miRNAs was observed in CRPC cases with high blood AR levels. For PFS prediction a tandem of miR‐429 and high AR reached HR of 5.0 (95% CI: 2.2–11.8, p < 0.001), while for prediction of OS the best combination was demonstrated by miR‐148a and AR with HR of 3.1 (95% CI: 1.4–7.1, p = 0.006).Conclusions: Urinary miRNAs could be used as prognostic biomarkers for CRPC patients to predict response to AA therapy, especially for the cases with high blood AR levels.
- 1 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3416
Multi-parametric MRI performance using PI-RADS v2 in detecting clinically significant prostate cancer after negative biopsy and persisting suspicion of malignancy
- 1 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3416
Multi-parametric MRI performance using PI-RADS v2 in detecting clinically significant prostate cancer after negative biopsy and persisting suspicion of malignancy
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2437
Whether p2PSA, %p2PSA and Prostate Health Index improves clinically significant prostate cancer detection in men with PSA range 2-10 ng/ml
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2437
Whether p2PSA, %p2PSA and Prostate Health Index improves clinically significant prostate cancer detection in men with PSA range 2-10 ng/ml
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2436
The ability of different clinical-pathological criteria’s to detect insignificant prostate cancer after transperineal template mapping biopsies
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2436
The ability of different clinical-pathological criteria’s to detect insignificant prostate cancer after transperineal template mapping biopsies
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2427-e2428
Diagnostic performance of PCA3 and TMPRSS2:ERG biomarkers in prostate cancer patients urine collected with and without prostate massage
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2427-e2428
Diagnostic performance of PCA3 and TMPRSS2:ERG biomarkers in prostate cancer patients urine collected with and without prostate massage
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2516
Novel DNA methylation biomarkers of clear cell renal carcinoma
- 1 May 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (3) , e2516
Novel DNA methylation biomarkers of clear cell renal carcinoma
- Open Access
- 8 January 2019
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 25 (3) , 151-160
Trends in the incidence and mortality of kidney cancer in Lithuania from 1993 to 2012
Background. The aim of this paper is to analyse trends of kidney cancer incidence and mortality in Lithuania during the period of 1993 to 2012 using joinpoint regression models with special attention to changes in the distribution of stages. Materials and methods. The study was based on all cases of kidney cancer reported to the Lithuanian Cancer Registry between 1993 and 2012. Age group-specific rates and standardized rates were calculated for each sex, using the direct method (world standard population). The joinpoint regression model was used to provide the estimated annual percentage change and to detect points in time where significant changes in the trends occur. Results. During the study period the age-standardized incidence rates increased from 16.89/100,000 in 1993 to 27.77/100,000 in 2012 in males, and from 7.95/100,000 to 13.44/100,000 in females. During this period, annual percentage changes in the age-standardized rates were 2.33% and 1.81% for males and females, respectively. The joinpoint analysis by stage of disease showed the highest increase in stage I kidney cancer, with statistically significant trend change in 2002 for males and in 2001 for females. During the study period, age-standardized mortality rates decreased from 10.42/100,000 in 1993 to 8.96/100,000 in 2012 in males, and from 4.54/100,000 to 3.9/100,000 in females. Conclusions. The kidney cancer incidence rate in Lithuania rose during the period of 1993 to 2012. The detailed analysis by stage showed the most significant increase in organ-confined incidence of kidney cancer. A stable mortality trend for males and a decreasing mortality trend for females along with increased incidence of early stage kidney cancer indicate that both earlier detection and modern treatment modalities may contribute to the reduction of mortality.
- 8 January 2019
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 25 (3) , 151-160
Open AccessTrends in the incidence and mortality of kidney cancer in Lithuania from 1993 to 2012
Background. The aim of this paper is to analyse trends of kidney cancer incidence and mortality in Lithuania during the period of 1993 to 2012 using joinpoint regression models with special attention to changes in the distribution of stages. Materials and methods. The study was based on all cases of kidney cancer reported to the Lithuanian Cancer Registry between 1993 and 2012. Age group-specific rates and standardized rates were calculated for each sex, using the direct method (world standard population). The joinpoint regression model was used to provide the estimated annual percentage change and to detect points in time where significant changes in the trends occur. Results. During the study period the age-standardized incidence rates increased from 16.89/100,000 in 1993 to 27.77/100,000 in 2012 in males, and from 7.95/100,000 to 13.44/100,000 in females. During this period, annual percentage changes in the age-standardized rates were 2.33% and 1.81% for males and females, respectively. The joinpoint analysis by stage of disease showed the highest increase in stage I kidney cancer, with statistically significant trend change in 2002 for males and in 2001 for females. During the study period, age-standardized mortality rates decreased from 10.42/100,000 in 1993 to 8.96/100,000 in 2012 in males, and from 4.54/100,000 to 3.9/100,000 in females. Conclusions. The kidney cancer incidence rate in Lithuania rose during the period of 1993 to 2012. The detailed analysis by stage showed the most significant increase in organ-confined incidence of kidney cancer. A stable mortality trend for males and a decreasing mortality trend for females along with increased incidence of early stage kidney cancer indicate that both earlier detection and modern treatment modalities may contribute to the reduction of mortality.